-
1 Comment
Synairgen plc is currently in a long term uptrend where the price is trading 4.8% above its 200 day moving average.
From a valuation standpoint, the stock is 70.4% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 759.0.
Based on the above factors, Synairgen plc gets an overall score of 1/5.
Exchange | LSE |
---|---|
CurrencyCode | GBP |
ISIN | GB00B0381Z20 |
Sector | Healthcare |
Industry | Biotechnology |
Target Price | 8 |
---|---|
Market Cap | 12M |
PE Ratio | None |
Beta | -2.23 |
Dividend Yield | None |
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of severe viral lung infections that is in pre- clinical trial; and inhaled interferon beta IFN-ß, a naturally occurring protein that helps regulate the immune system to fight viruses, including coronaviruses. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for SNG.LSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025